CureVac N.V. - Ordinary Shares (CVAC) Covered Calls
You can sell covered calls on CureVac N.V. - Ordinary Shares to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for CVAC (prices last updated Tue 3:25 PM ET):
| CureVac N.V. - Ordinary Shares (CVAC) Stock Quote | ||||||
|---|---|---|---|---|---|---|
| Last | Change | Bid | Ask | Volume | P/E | Market Cap |
| 2.98 | +0.04 | 2.98 | 2.99 | 328K | - | 0.5 |
| Covered Calls For CureVac N.V. - Ordinary Shares (CVAC) | ||||||
|---|---|---|---|---|---|---|
| Expiration | Strike | Call Bid | Net Debit | Return If Flat |
Annualized Return If Flat |
|
| May 17 | 2.5 | 0.00 | 2.99 | -16.4% | -544.2% | |
| Jun 21 | 2.5 | 0.55 | 2.44 | 2.5% | 19.8% | |
| Subscribers get access to the full covered call chain, and more features. | ||||||
Want to make money with covered calls? Sign Up For A Free Trial
Extended Business Description
CureVac N.V., a clinical-stage biopharmaceutical company, engages in developing various transformative medicines based on messenger ribonucleic acid (mRNA). Its lead proprietary programs include CV8102 that is in a Phase 1 dose escalating clinical trials for four types of cancers as a monotherapy and in combination with anti-PD-1; and CV7202, which is in a Phase 1 clinical trials as a vaccine candidate against rabies. It is also advancing mRNA vaccine program against coronavirus (SARS-CoV-2), which is in Phase 1 clinical trial. The company's partnered programs comprise BI1361849, a therapeutic vaccine candidate that is in a Phase 1/2 clinical trials to elicit antigen-specific immune responses against tumor-associated antigens frequently overexpressed in patients with non-small cell lung cancer; Cas9 mRNA constructs for use in gene editing therapeutics; mRNA based novel therapeutic antibodies; prophylactic vaccines to prevent picornaviruses, influenza, malaria, and rotavirus; and programs against SARS-CoV-2, Lassa virus, and yellow fever. It has strategic partnerships with Genmab, Arcturus, Acuitas, CRISPR Therapeutics, Boehringer Ingelheim, GlaxoSmithKline, the Bill & Melinda Gates Foundation, CEPI, Tesla Grohmann, and others. The company was founded in 2000 and is headquartered in Tübingen, Germany.
| Top 10 Open Interest For May 17 Expiration | Top 5 High Yield | |||||
|---|---|---|---|---|---|---|
| 1. | IWM covered calls | 6. | EEM covered calls | 1. | RIVN covered calls | |
| 2. | QQQ covered calls | 7. | TSLA covered calls | 2. | LYFT covered calls | |
| 3. | SPY covered calls | 8. | SLV covered calls | 3. | UPST covered calls | |
| 4. | HYG covered calls | 9. | TLT covered calls | 4. | AAOI covered calls | |
| 5. | FXI covered calls | 10. | NVDA covered calls | 5. | TOST covered calls | |
Want more examples? CUZ Covered Calls | CVBF Covered Calls
